<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Li-Fraumeni Syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Li-Fraumeni Syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Li-Fraumeni Syndrome</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0018875" target="_blank">
                        MONDO:0018875
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">hereditary cancer-predisposing syndrome</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome caused by germline pathogenic variants in the TP53 tumor suppressor gene. It is characterized by a dramatically increased lifetime risk of multiple cancers, including soft tissue sarcomas, osteosarcomas, breast cancer, brain tumors, adrenocortical carcinoma, and leukemias. LFS exemplifies the two-hit hypothesis: patients inherit one mutant TP53 allele and somatic loss of the remaining wild-type allele initiates tumorigenesis. The syndrome demonstrates remarkable phenotypic variability, with some carriers developing multiple primary cancers while others remain cancer-free.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Classic Li-Fraumeni Syndrome</div>
                
                <div class="item-desc">Defined by classic clinical criteria: proband with sarcoma before age 45, first-degree relative with cancer before 45, and another first- or second-degree relative with cancer before 45 or sarcoma at any age.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Li-Fraumeni-Like Syndrome</div>
                
                <div class="item-desc">Families meeting relaxed criteria (Birch or Eeles) who have germline TP53 mutations but do not fulfill classic LFS criteria. May have later onset or fewer affected family members.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TP53 Tumor Suppressor Loss</div>
                
                <div class="item-desc">Germline heterozygous TP53 mutations result in haploinsufficiency for p53 function. Somatic loss or inactivation of the remaining wild-type allele (second hit) eliminates p53 tumor suppressor activity, removing a critical checkpoint against malignant transformation.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        signal transduction by p53 class mediator
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0072331" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Loss of DNA Damage Response</div>
                
                <div class="item-desc">p53 is a master regulator of the DNA damage response. Upon detecting DNA damage, p53 activates transcription of genes involved in cell cycle arrest, DNA repair, and apoptosis. Loss of p53 function eliminates this critical surveillance mechanism.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        DNA damage response, signal transduction by p53 class mediator
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030330" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Loss of Cell Cycle Checkpoint Control</div>
                
                <div class="item-desc">p53 induces G1 arrest in response to DNA damage by activating p21 (CDKN1A) transcription, which inhibits cyclin-dependent kinases. Without p53, cells with damaged DNA continue through the cell cycle, replicating mutations.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        G1/S transition of mitotic cell cycle
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000082" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚ö† ABNORMAL
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired Apoptosis</div>
                
                <div class="item-desc">p53 promotes apoptosis through transcriptional activation of pro-apoptotic genes (BAX, PUMA, NOXA) and repression of anti-apoptotic BCL2. Loss of p53 allows damaged and potentially transformed cells to survive and proliferate.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        intrinsic apoptotic signaling pathway by p53 class mediator
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0072332" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        apoptotic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006915" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Genomic Instability</div>
                
                <div class="item-desc">Loss of p53-mediated checkpoints and DNA repair coordination leads to progressive accumulation of genomic alterations including point mutations, chromosomal rearrangements, and aneuploidy. This genomic instability accelerates tumor development and drives cancer heterogeneity.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        DNA repair
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006281" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Tumor Development</div>
                
                <div class="item-desc">The combination of impaired DNA damage response, loss of cell cycle checkpoints, defective apoptosis, and genomic instability creates a permissive environment for tumor development. Different tissues vary in susceptibility, explaining the characteristic cancer spectrum of LFS.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Loss_of_DNA_Damage_Response[&#34;Loss of DNA Damage Response&#34;]
    Genomic_Instability[&#34;Genomic Instability&#34;]
    TP53_Tumor_Suppressor_Loss[&#34;TP53 Tumor Suppressor Loss&#34;]
    Tumor_Development[&#34;Tumor Development&#34;]
    Impaired_Apoptosis[&#34;Impaired Apoptosis&#34;]
    Loss_of_Cell_Cycle_Checkpoint_Control[&#34;Loss of Cell Cycle Checkpoint Control&#34;]

    TP53_Tumor_Suppressor_Loss --&gt; Loss_of_DNA_Damage_Response
    TP53_Tumor_Suppressor_Loss --&gt; Loss_of_Cell_Cycle_Checkpoint_Control
    TP53_Tumor_Suppressor_Loss --&gt; Impaired_Apoptosis
    Loss_of_DNA_Damage_Response --&gt; Genomic_Instability
    Loss_of_Cell_Cycle_Checkpoint_Control --&gt; Genomic_Instability
    Impaired_Apoptosis --&gt; Tumor_Development
    Genomic_Instability --&gt; Tumor_Development

    style Loss_of_DNA_Damage_Response fill:#dbeafe
    style Genomic_Instability fill:#dbeafe
    style TP53_Tumor_Suppressor_Loss fill:#dbeafe
    style Tumor_Development fill:#dbeafe
    style Impaired_Apoptosis fill:#dbeafe
    style Loss_of_Cell_Cycle_Checkpoint_Control fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Soft Tissue Sarcoma
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0030448" target="_blank">
                            HP:0030448
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26014290" target="_blank">PMID:26014290</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast..."</div>
                
                
                <div class="evidence-explanation">French cohort study of 415 TP53 mutation carriers demonstrates soft tissue sarcomas are a core tumor type in LFS, occurring in 23% of children and 27% of adults.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Osteosarcoma
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002669" target="_blank">
                            HP:0002669
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Breast Cancer
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0003002" target="_blank">
                            HP:0003002
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26014290" target="_blank">PMID:26014290</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients."</div>
                
                
                <div class="evidence-explanation">French cohort study demonstrates breast cancer is the predominant tumor type in adult females with LFS, occurring in 79% of affected women.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Adrenocortical Carcinoma
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0006744" target="_blank">
                            HP:0006744
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Central Nervous System Tumors
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100836" target="_blank">
                            HP:0100836
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Leukemia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002488" target="_blank">
                            HP:0002488
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Multiple Primary Cancers
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                            HP:0002664
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26014290" target="_blank">PMID:26014290</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18."</div>
                
                
                <div class="evidence-explanation">Large French cohort demonstrates that 43% of LFS patients develop multiple malignancies, with average 1.7 tumors per affected carrier.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TP53
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Germline Loss-of-Function Mutations)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26014290" target="_blank">PMID:26014290</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The mean age of tumor onset was statistically different (P &lt; .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC,..."</div>
                
                
                <div class="evidence-explanation">Clinical gradient of germline TP53 mutations demonstrates that dominant-negative missense mutations cause earlier tumor onset (21.3 years) compared to loss-of-function mutations (28.5 years), supporting mutation-specific phenotype stratification.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cancer Surveillance Protocol
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000126" target="_blank">
                            MAXO:0000126
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28572266" target="_blank">PMID:28572266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"the panel recommends adoption of a modified version of the &#34;Toronto protocol&#34; that includes a combination of physical exams, blood tests, and imaging. The panel also recommends that further research be promoted to explore the feasibility and effectiveness of these risk-adapted surveillance and..."</div>
                
                
                <div class="evidence-explanation">AACR expert panel consensus recommends the Toronto Protocol surveillance approach for all LFS patients as soon as diagnosis is established.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Risk-Reducing Mastectomy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Radiation Avoidance
                    
                </div>
                
                <div class="item-desc">Radiation therapy should be avoided when possible in LFS patients due to increased risk of radiation-induced secondary malignancies. Alternative treatment modalities should be considered.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    TP53 Genetic Testing
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Li-Fraumeni Syndrome
description: &gt;-
  Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome
  caused by germline pathogenic variants in the TP53 tumor suppressor gene. It is
  characterized by a dramatically increased lifetime risk of multiple cancers, including
  soft tissue sarcomas, osteosarcomas, breast cancer, brain tumors, adrenocortical
  carcinoma, and leukemias. LFS exemplifies the two-hit hypothesis: patients inherit
  one mutant TP53 allele and somatic loss of the remaining wild-type allele initiates
  tumorigenesis. The syndrome demonstrates remarkable phenotypic variability, with
  some carriers developing multiple primary cancers while others remain cancer-free.
categories:
- Hereditary Cancer Syndrome
- Cancer Predisposition Syndrome
parents:
- hereditary cancer-predisposing syndrome
has_subtypes:
- name: Classic Li-Fraumeni Syndrome
  description: &gt;-
    Defined by classic clinical criteria: proband with sarcoma before age 45,
    first-degree relative with cancer before 45, and another first- or second-degree
    relative with cancer before 45 or sarcoma at any age.
- name: Li-Fraumeni-Like Syndrome
  description: &gt;-
    Families meeting relaxed criteria (Birch or Eeles) who have germline TP53
    mutations but do not fulfill classic LFS criteria. May have later onset
    or fewer affected family members.
pathophysiology:
- name: TP53 Tumor Suppressor Loss
  description: &gt;-
    Germline heterozygous TP53 mutations result in haploinsufficiency for p53
    function. Somatic loss or inactivation of the remaining wild-type allele
    (second hit) eliminates p53 tumor suppressor activity, removing a critical
    checkpoint against malignant transformation.
  biological_processes:
  - preferred_term: signal transduction by p53 class mediator
    modifier: DECREASED
    term:
      id: GO:0072331
      label: signal transduction by p53 class mediator
  downstream:
  - target: Loss of DNA Damage Response
    description: p53 loss impairs cellular response to genotoxic stress
  - target: Loss of Cell Cycle Checkpoint Control
    description: p53 loss allows cells with DNA damage to continue cycling
  - target: Impaired Apoptosis
    description: p53 loss prevents elimination of damaged cells
- name: Loss of DNA Damage Response
  description: &gt;-
    p53 is a master regulator of the DNA damage response. Upon detecting DNA
    damage, p53 activates transcription of genes involved in cell cycle arrest,
    DNA repair, and apoptosis. Loss of p53 function eliminates this critical
    surveillance mechanism.
  biological_processes:
  - preferred_term: DNA damage response, signal transduction by p53 class mediator
    modifier: DECREASED
    term:
      id: GO:0030330
      label: DNA damage response, signal transduction by p53 class mediator
  downstream:
  - target: Genomic Instability
    description: Unchecked DNA damage leads to mutation accumulation
- name: Loss of Cell Cycle Checkpoint Control
  description: &gt;-
    p53 induces G1 arrest in response to DNA damage by activating p21 (CDKN1A)
    transcription, which inhibits cyclin-dependent kinases. Without p53, cells
    with damaged DNA continue through the cell cycle, replicating mutations.
  biological_processes:
  - preferred_term: G1/S transition of mitotic cell cycle
    modifier: ABNORMAL
    term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
  downstream:
  - target: Genomic Instability
    description: Damaged cells replicate, accumulating mutations
- name: Impaired Apoptosis
  description: &gt;-
    p53 promotes apoptosis through transcriptional activation of pro-apoptotic
    genes (BAX, PUMA, NOXA) and repression of anti-apoptotic BCL2. Loss of p53
    allows damaged and potentially transformed cells to survive and proliferate.
  biological_processes:
  - preferred_term: intrinsic apoptotic signaling pathway by p53 class mediator
    modifier: DECREASED
    term:
      id: GO:0072332
      label: intrinsic apoptotic signaling pathway by p53 class mediator
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  downstream:
  - target: Tumor Development
    description: Damaged cells escape elimination and undergo malignant transformation
- name: Genomic Instability
  description: &gt;-
    Loss of p53-mediated checkpoints and DNA repair coordination leads to
    progressive accumulation of genomic alterations including point mutations,
    chromosomal rearrangements, and aneuploidy. This genomic instability
    accelerates tumor development and drives cancer heterogeneity.
  biological_processes:
  - preferred_term: DNA repair
    modifier: DECREASED
    term:
      id: GO:0006281
      label: DNA repair
  downstream:
  - target: Tumor Development
    description: Accumulated mutations drive malignant transformation
- name: Tumor Development
  description: &gt;-
    The combination of impaired DNA damage response, loss of cell cycle checkpoints,
    defective apoptosis, and genomic instability creates a permissive environment
    for tumor development. Different tissues vary in susceptibility, explaining
    the characteristic cancer spectrum of LFS.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
phenotypes:
- category: Neoplastic
  name: Soft Tissue Sarcoma
  frequency: VERY_FREQUENT
  description: &gt;-
    Soft tissue sarcomas, particularly rhabdomyosarcoma in children and
    undifferentiated pleomorphic sarcoma in adults, are core tumors of LFS.
    Often present at young ages.
  phenotype_term:
    preferred_term: Soft tissue sarcoma
    term:
      id: HP:0030448
      label: Soft tissue sarcoma
  evidence:
  - reference: PMID:26014290
    supports: SUPPORT
    snippet: &gt;-
      In childhood, the LFS tumor spectrum was characterized by osteosarcomas,
      adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS)
      observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults,
      the tumor distribution was characterized by the predominance of breast
      carcinomas observed in 79% of the females, and STS observed in 27% of the patients.
    explanation: &gt;-
      French cohort study of 415 TP53 mutation carriers demonstrates soft tissue
      sarcomas are a core tumor type in LFS, occurring in 23% of children and
      27% of adults.
- category: Neoplastic
  name: Osteosarcoma
  frequency: FREQUENT
  description: &gt;-
    Osteosarcoma is a core tumor of LFS, typically occurring in adolescence
    or young adulthood. Often affects the long bones.
  phenotype_term:
    preferred_term: Osteosarcoma
    term:
      id: HP:0002669
      label: Osteosarcoma
- category: Neoplastic
  name: Breast Cancer
  frequency: VERY_FREQUENT
  description: &gt;-
    Premenopausal breast cancer is a hallmark of female LFS patients. Lifetime
    risk approaches 85-90% in women. Often HER2-positive. Occurs at much younger
    ages than sporadic breast cancer.
  phenotype_term:
    preferred_term: Breast carcinoma
    term:
      id: HP:0003002
      label: Breast carcinoma
  evidence:
  - reference: PMID:26014290
    supports: SUPPORT
    snippet: &gt;-
      In adults, the tumor distribution was characterized by the predominance of
      breast carcinomas observed in 79% of the females, and STS observed in 27%
      of the patients.
    explanation: &gt;-
      French cohort study demonstrates breast cancer is the predominant tumor
      type in adult females with LFS, occurring in 79% of affected women.
- category: Neoplastic
  name: Adrenocortical Carcinoma
  frequency: FREQUENT
  description: &gt;-
    Pediatric adrenocortical carcinoma is highly associated with LFS. Most
    children with ACC should be tested for germline TP53 mutations.
    The R337H Brazilian founder mutation is particularly associated with ACC.
  phenotype_term:
    preferred_term: Adrenocortical carcinoma
    term:
      id: HP:0006744
      label: Adrenocortical carcinoma
- category: Neoplastic
  name: Central Nervous System Tumors
  frequency: FREQUENT
  description: &gt;-
    Brain tumors including gliomas, choroid plexus carcinoma, and medulloblastoma
    occur with increased frequency. Choroid plexus carcinoma in childhood is
    highly suggestive of LFS.
  phenotype_term:
    preferred_term: Malignant neoplasm of the central nervous system
    term:
      id: HP:0100836
      label: Malignant neoplasm of the central nervous system
- category: Neoplastic
  name: Leukemia
  frequency: OCCASIONAL
  description: &gt;-
    Acute leukemias, both lymphoblastic and myeloid, occur at increased
    frequency in LFS patients, often at young ages.
  phenotype_term:
    preferred_term: Acute leukemia
    term:
      id: HP:0002488
      label: Acute leukemia
- category: Neoplastic
  name: Multiple Primary Cancers
  frequency: FREQUENT
  description: &gt;-
    Many LFS patients develop multiple independent primary cancers during
    their lifetime. This is a characteristic feature distinguishing LFS
    from sporadic cancer cases.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:26014290
    supports: SUPPORT
    snippet: &gt;-
      The 322 affected carriers developed 552 tumors, and 43% had developed
      multiple malignancies. The mean age of first tumor onset was 24.9 years,
      41% having developed a tumor by age 18.
    explanation: &gt;-
      Large French cohort demonstrates that 43% of LFS patients develop multiple
      malignancies, with average 1.7 tumors per affected carrier.
biochemical:
- name: TP53 Genetic Testing
  notes: &gt;-
    Molecular testing of TP53 identifies germline pathogenic variants including
    missense mutations (especially in the DNA-binding domain), nonsense mutations,
    frameshift mutations, and splice site variants. Certain mutations (R175H,
    R248W, R273H) have dominant-negative effects.
genetic:
- name: TP53
  association: Germline Loss-of-Function Mutations
  inheritance:
  - name: Autosomal Dominant
  notes: &gt;-
    TP53 (17p13.1) encodes the p53 tumor suppressor protein. Germline pathogenic
    variants cause LFS with high but incomplete penetrance. Most mutations are
    missense variants in the DNA-binding domain (exons 5-8). Some mutations
    (R175H, R248Q, R248W, R273H, R273C) have dominant-negative effects beyond
    simple loss of function. The Brazilian founder mutation R337H has attenuated
    penetrance but high association with adrenocortical carcinoma.
  evidence:
  - reference: PMID:26014290
    supports: SUPPORT
    snippet: &gt;-
      The mean age of tumor onset was statistically different (P &lt; .05) between
      carriers harboring dominant-negative missense mutations (21.3 years) and
      those with all types of loss of function mutations (28.5 years) or genomic
      rearrangements (35.8 years). Affected children, except those with ACC,
      harbored mostly dominant-negative missense mutations.
    explanation: &gt;-
      Clinical gradient of germline TP53 mutations demonstrates that dominant-negative
      missense mutations cause earlier tumor onset (21.3 years) compared to loss-of-function
      mutations (28.5 years), supporting mutation-specific phenotype stratification.
treatments:
- name: Cancer Surveillance Protocol
  description: &gt;-
    Intensive cancer surveillance (Toronto Protocol) includes annual whole-body
    MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical
    markers. Early detection significantly improves outcomes. Surveillance
    should begin in childhood.
  treatment_term:
    preferred_term: cancer screening
    term:
      id: MAXO:0000126
      label: cancer screening
  evidence:
  - reference: PMID:28572266
    supports: SUPPORT
    snippet: &gt;-
      the panel recommends adoption of a modified version of the &#34;Toronto protocol&#34;
      that includes a combination of physical exams, blood tests, and imaging.
      The panel also recommends that further research be promoted to explore the
      feasibility and effectiveness of these risk-adapted surveillance and cancer
      prevention strategies.
    explanation: &gt;-
      AACR expert panel consensus recommends the Toronto Protocol surveillance
      approach for all LFS patients as soon as diagnosis is established.
- name: Risk-Reducing Mastectomy
  description: &gt;-
    Prophylactic bilateral mastectomy may be considered for women with LFS
    given the extremely high lifetime breast cancer risk (85-90%). Decision
    requires careful counseling about risks and benefits.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Genetic Counseling
  description: &gt;-
    Genetic counseling is essential for affected families to discuss inheritance,
    testing of at-risk relatives, reproductive options, and psychological support.
    Cascade testing of family members is recommended.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
- name: Radiation Avoidance
  description: &gt;-
    Radiation therapy should be avoided when possible in LFS patients due to
    increased risk of radiation-induced secondary malignancies. Alternative
    treatment modalities should be considered.
  notes: &gt;-
    p53 is critical for radiation-induced apoptosis and cell cycle arrest.
    LFS patients are exquisitely sensitive to radiation-induced carcinogenesis.
disease_term:
  preferred_term: Li-Fraumeni syndrome
  term:
    id: MONDO:0018875
    label: Li-Fraumeni syndrome
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Li-Fraumeni_Syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>